Claudio Giuliano Selected Research

HM01

1/2020	The brain-penetrating, orally bioavailable, ghrelin receptor agonist HM01 ameliorates motion-induced emesis in Suncus murinus (house musk shrew).
1/2019	A Comparison of the Central versus Peripheral Gastrointestinal Prokinetic Activity of Two Novel Ghrelin Mimetics.
1/2018	Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT3 Antagonist, Palonosetron and With the NK1 Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew).
1/2018	Corrigendum: Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT3 Antagonist, Palonosetron and With the NK1 Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew).
5/2017	Oral Treatment with the Ghrelin Receptor Agonist HM01 Attenuates Cachexia in Mice Bearing Colon-26 (C26) Tumors.
1/2016	The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claudio Giuliano Research Topics

Disease

5	Vomiting 01/2020 - 01/2014
4	Parkinson Disease (Parkinson's Disease) 08/2021 - 01/2019
4	Infections 01/2011 - 07/2005
3	Body Weight (Weight, Body) 12/2017 - 01/2016
3	Neoplasms (Cancer) 05/2017 - 09/2011
2	Motion Sickness (Airsickness) 01/2020 - 01/2018
2	Metabolic Diseases (Metabolic Disease) 12/2018 - 12/2017
2	Obesity 12/2018 - 12/2017
2	Nausea 01/2018 - 01/2014
2	Cachexia 05/2017 - 01/2016
2	Anorexia 05/2017 - 01/2016
1	Disease Progression 08/2021
1	Ileus 01/2019
1	Type 2 Diabetes Mellitus (MODY) 12/2018
1	Weight Gain 01/2018
1	Diabetes Mellitus 12/2017
1	Hepatocellular Carcinoma (Hepatoma) 01/2016
1	AIDS-Related Complex (ARC) 01/2016
1	Hepatitis C 08/2012

Drug/Important Bio-Agent (IBA)

6	HM01IBA 01/2020 - 01/2016
6	Ghrelin ReceptorsIBA 01/2020 - 01/2016
4	GhrelinIBA 12/2018 - 01/2016
4	netupitantIBA 01/2018 - 01/2014
3	muskIBA 01/2020 - 01/2018
3	Palonosetron (Aloxi)FDA Link 01/2018 - 01/2016
3	AntiemeticsIBA 01/2018 - 01/2016
3	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 01/2016
2	Copper Sulfate (Sulfate, Copper)FDA Link 01/2018 - 01/2016
2	EmeticsIBA 01/2018 - 01/2016
2	Serotonin 5-HT3 Receptor AntagonistsIBA 01/2018 - 01/2018
1	CannabidiolIBA 08/2021
1	PolyphenolsIBA 02/2021
1	Therapeutic UsesIBA 02/2021
1	hydroxymatairesinolIBA 01/2020
1	LignansIBA 01/2020
1	Neuroprotective AgentsIBA 01/2020
1	Glucosylceramidase (Glucocerebrosidase)IBA 01/2019
1	Urea (Carbamide)FDA LinkGeneric 01/2018
1	Nicotine FDA Link 01/2018
1	LipidsIBA 12/2017
1	Glucose (Dextrose)FDA LinkGeneric 12/2017
1	CytokinesIBA 05/2017
1	Interleukin-6 (Interleukin 6)IBA 05/2017
1	Morphine (MS Contin)FDA LinkGeneric 01/2016
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2016
1	Apomorphine FDA Link 01/2016
1	Serotonin (5 Hydroxytryptamine)IBA 01/2016
1	Substance PIBA 01/2016
1	TachykininsIBA 01/2016
1	Ondansetron (Zofran)FDA LinkGeneric 01/2016
1	Aprepitant (Emend)FDA Link 01/2016
1	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 01/2016
1	Antiviral Agents (Antivirals)IBA 08/2012
1	7-deaza-adenine nucleosideIBA 08/2012
1	phosphoramidic acidIBA 09/2009
1	ProdrugsIBA 09/2009
1	2'-C-methylcytidineIBA 09/2009
1	Ribavirin (Virazole)FDA LinkGeneric 09/2009
1	InterferonsIBA 09/2009

Therapy/Procedure

6	Therapeutics 08/2021 - 07/2005
3	Drug Therapy (Chemotherapy) 01/2018 - 01/2014
1	Aftercare (After-Treatment) 01/2018